Casdin Capital’s Blueprint Medicines BPMC Stock Holding History

Casdin Capital’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-10,000	Closed	-$635K	–	37
2018 Q2	$635K	Buy	+10,000	New	+$796K	0.09%	35

Other funds holding BPMC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Casdin Capital's BPMC Position: Q2 2025 in Review

Casdin Capital sold out of Blueprint Medicines (BPMC) in Q2 2025, closing a stake of 326,378 shares — an estimated $28.9M sold.

Casdin Capital first reported a position in BPMC in Q4 2015 and held it in 38 quarters. The position peaked at $174M in Q4 2020. 354 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.

Casdin Capital reported no remaining Blueprint Medicines position as of Q2 2025 after selling out during the quarter.
Casdin Capital sold 326,378 Blueprint Medicines shares in Q2 2025, an estimated $28.9M.
Casdin Capital first reported a position in Blueprint Medicines in Q4 2015 and held it in 38 quarters.
Casdin Capital's Blueprint Medicines position peaked at $174M in Q4 2020.
354 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.

Based on Casdin Capital's 13F filing for Q2 2025, filed 14 Aug 2025.